Adults ≥50 years with polymyalgia rheumatica according to the EULAR/ACR classification criteria
Meet criteria for newly diagnosed PMR (received ≤6 weeks of corticosteroids prior to randomization) or for early relapsing PMR (initiated corticosteroid treatment within last year, treated with prednisone ≥10 mg/day for ≥ 8 weeks, and experienced flare within prior 12 weeks while receiving ≥5 mg/d prednisone)
Participants must be willing and able to take prednisone of 15 mg/day at randomization
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Exclusion related to tuberculosis (TB), invasive opportunistic infections, recurrent or persistent infections including hepatitis B, C or HIV, recurrent herpes zoster or active herpes zoster
Patients with uncontrolled diabetes mellitus (HbA1c ≥9%)
Immunosuppressive therapies including systemic corticosteroids
Malignancy
Organ transplant recipient
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
